SUPPLEMENTAL MATERIAL

	Year of follow-up										
Year of	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
diagnosis											
2003	1	1/2	2/3	3/4	4/5	5/6	6/7	7/8	8/9	9/10	10/11
2004		1	1/2	2/3	3/4	4/5	5/6	6/7	7/8	8/9	9/10
2005			1	1/2	2/3	3/4	4/5	5/6	6/7	7/8	8/9
2006				1	1/2	2/3	3/4	4/5	5/6	6/7	7/8
2007					1	1/2	2/3	3/4	4/5	5/6	6/7
2008						1	1/2	2/3	3⁄4	4/5	5/6
2009							1	1/2	2/3	3/4	4/5
2010								1	1⁄2	2/3	3/4
2011									1	1/2	2/3
2012										1	1/2
2013											1

Table S1. Years of diagnosis and years of follow-up

	STEMI N=60,712	NSTEMI N=119,656
Age	0	0
Male (%)	0	0
Year of hospitalisation	-	· · ·
2003-05	0	0
2006-08	0	0
2009-11	0	0
2012-13	0	0
Risk factors	•	
Diabetes mellitus	0	0
Hypertension	0	0
Current/ex-smoker	4,813 (7.9%)	11,270 (9.4%)
Prior cardiovascular diseases		
Myocardial infarction	0	0
Heart failure	0	0
PCI	0	0
CABG	0	0
Cerebrovascular disease	0	0
PVD	0	0
Other comorbidities		
Chronic renal failure	0	0
COPD	0	0
Presenting clinical characteri	stics	
Systolic BP	9,597 (15.8%)	19,153 (16.0%)
Heart rate	9,015 (14.9%)	17,802 (14.9%)
ST-segment deviation	213 (0.4%)	2,152 (1.8%)
In-hospital course		
Cardiac arrest	13 (0.0%)	58 (0.1%)
Loop diuretic administration	347 (0.6%)	678 (0.6%)
Reperfusion	842 (1.4%)	-
Revascularisation	0	0
Guideline-indicated treatment		I
Aspirin	673 (1.1%)	957 (0.8%)
β–blockers	582 (1.0%)	865 (0.7%)
Statin	610 (1.0%)	950 (0.8%)
ACEi or ARB	4,291 (7.1%)	8,888 (7.4%)
P2Y ₁₂ inhibitors	552 (0.9%)	829 (0.7%)

Table S2. Baseline and clinical characteristics for the 2003-2013 AMI cohort with missing levels,

stratified by clinical presentation

Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; BP, blood pressure; reperfusion, fibrinolysis or primary percutaneous coronary intervention [PCI]; revascularisation, PCI or coronary artery bypass graft [CABG] surgery ACEi, angiotensin converting enzyme ARB, angiotensin receptor blocker; -, not applicable.

	STEMI N=60,712											
		Women (N=20,140)						Men (N=40,572)				
	≤55	55-65	66-75	76-85	>85	≤55	55-65	66-75	76-85	>85		
Diabetes	292 (16.1%)	482 (15.1%)	888 (18.1%)	1,310 (19.2%)	552 (16.2%)	809 (10.5%)	1,573 (13.6%)	1,758 (16.1%)	1,505 (18.3%)	327 (15.0%)		
Myocardial infarction	88 (4.9%)	230 (7.2%)	465 (9.5%)	930 (13.7%)	633 (18.6%)	466 (6.1%)	1,093 (9.4%)	1,511 (13.9%)	1,690 (20.6%)	518 (23.7%)		
Heart failure	27 (1.5%)	53 (1.7%)	179 (3.7%)	540 (7.9%)	470 (13.8%)	56 (0.7%)	181 (1.6%)	387 (3.6%)	645 (7.8%)	257 (11.8%)		
PCI	57 (3.2%)	145 (4.5%)	219 (4.5%)	216 (3.2%)	84 (2.5%)	327 (4.3%)	732 (6.3%)	772 (7.1%)	535 (6.5%)	74 (3.4%)		
CABG	15 (0.8%)	50 (1.6%)	117 (2.4%)	178 (2.6%)	55 (1.6%)	103 (1.3%)	341 (2.9%)	562 (5.2%)	535 (6.5%)	85 (3.9%)		
Cerebrovascular disease	35 (1.9%)	123 (3.8%)	318 (6.5%)	807 (11.9%)	492 (14.4%)	125 (1.6%)	406 (3.5%)	788 (7.2%)	1,062 (12.9%)	365 (16.7%)		
PVD	26 (1.4%)	71 (2.2%)	212 (4.3%)	337 (5.0%)	187 (5.5%)	61 (0.8%)	212 (1.8%)	452 (4.2%)	435 (5.3%)	127 (5.8%)		
Chronic renal failure	31 (1.7%)	35 (1.1%)	82 (1.7%)	134 (2.0%)	90 (2.6%)	47 (0.6%)	127 (1.1%)	183 (1.7%)	254 (3.1%)	106 (4.9%)		
Hypertension	576 (31.8%)	1,310 (40.9%)	2,302 (46.9%)	3,672 (53.9%)	1,864 (54.7%)	1,797 (23.4%)	3,986 (34.4%)	4,370 (40.1%)	3,604 (43.8%)	944 (43.2%)		
COPD	45 (2.5%)	224 (7.0%)	419 (8.5%)	513 (7.5%)	157 (4.6%)	58 (0.8%)	320 (2.8%)	562 (5.2%)	576 (7.0%)	140 (6.4%)		

Table S3. Baseline characteristics stratified by sex and age group for STEMI

Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease.

ļ	1	NSTEMI N=119,656										
ļ ļ	I I	1	Women (N	J=45,254)	· · · · · ·	1	Men (N=74,402)					
	≤55	55-65	66-75	76-85	>85	≤55	55-65	66-75	76-85	>85		
Diabetes	536 (18.5%)	1,258 (22.1%)	2,759 (25.8%)	4,238 (24.9%)	1,719 (19.2%)	1,204 (13.7%)	3,409 (20.8%)	5,314 (25.3%)	5,188 (24.6%)	1,269 (18.1%)		
Myocardial infarction	213 (7.4%)	710 (12.5%)	1,979 (18.5%)	4,412 (25.9%)	2,812 (31.4%)	867 (9.8%)	2,808 (17.1%)	5,498 (26.1%)	7,329 (34.7%)	2,690 (38.4%)		
Heart failure	61 (2.1%)	252 (4.4%)	979 (9.2%)	2,793 (16.4%)	2,085 (23.3%)	183 (2.1%)	818 (6.0%)	2,130 (10.1%)	3,630 (17.2%)	1,621 (23.1%)		
PCI	130 (4.5%)	418 (7.3%)	903 (8.5%)	1,127 (6.6%)	279 (3.1%)	666 (7.6%)	1,729 (10.5%)	2,729 (13.0%)	2,230 (10.6%)	409 (5.8%)		
CABG	57 (2.0%)	246 (4.3%)	685 (6.4%)	1,154 (6.8%)	351 (3.9%)	275 (3.1%)	1,341 (8.2%)	2,966 (14.1%)	3,388 (16.0%)	729 (10.4%)		
Cerebrovascular disease	87 (3.0%)	298 (5.2%)	1,061 (9.9%)	2,484 (14.6%)	1,405 (15.7%)	199 (2.3%)	898 (5.5%)	2,258 (10.7%)	3,566 (16.9%)	1,268 (18.1%)		
PVD	61 (2.1%)	263 (4.6%)	709 (6.6%)	1,399 (8.2%)	689 (7.7%)	121 (1.4%)	571 (3.5%)	1,628 (7.7%)	2,169 (10.3%)	552 (7.9%)		
Chronic renal failure	87 (3.0%)	148 (2.6%)	343 (3.2%)	595 (3.5%)	349 (3.9%)	168 (1.9%)	364 (2.2%)	769 (3.7%)	1,231 (5.8%)	459 (6.5%)		
Hypertension	945 (32.7%)	2,589 (45.4%)	5,856 (54.8%)	10,005 (58.8%)	5,061 (56.6%)	2,631 (29.9%)	6,994 (42.6%)	10,260 (48.8%)	10,440 (49.4%)	3,111 (44.4%)		
COPD	94 (3.3%)	512 (9.0%)	1,333 (12.5%)	1,653 (9.7%)	538 (6.0%)	115 (1.3%)	704 (4.3%)	1,686 (8.0%)	2,109 (10.0%)	594 (8.5%)		

Table S4. Baseline characteristics stratified by sex and age group for NSTEMI

Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease.

Treatments at discharge		STEMI (N	N=60,712)	NSTEMI (N=119,656)				
	Unadjusted	P value	Adjusted*	P value	Unadjusted	P value	Adjusted*	P value
Aspirin	0.61 (0.57-0.64)	< 0.001	0.84 (0.79-0.89)	< 0.001	0.71 (0.69- 0.74)	< 0.001	0.85 (0.82-0.88)	< 0.001
β–blockers	0.67 (0.64-0.70)	< 0.001	0.88 (0.84-0.93)	< 0.001	0.83 (0.81-0.86)	< 0.001	0.97 (0.93-1.00)	0.047
Statin	0.47 (0.45-0.49)	< 0.001	0.76 (0.72-0.80)	< 0.001	0.54 (0.53-0.56)	< 0.001	0.75 (0.73-0.77)	< 0.001
ACEi or ARB	0.68 (0.65-0.71)	< 0.001	0.78 (0.74-0.81)	< 0.001	0.83 (0.81-0.85)	< 0.001	0.86 (0.84-0.89)	< 0.001
P2Y ₁₂ inhibitors	0.59 (0.57-0.61)	< 0.001	0.83 (0.80- 0.87)	< 0.001	0.70 (0.69-0.72)	< 0.001	0.87 (0.85-0.89)	< 0.001
Reperfusion	0.57 (0.55-0.59)	< 0.001	0.80 (0.77-0.84)	< 0.001	-	-	-	-
Revascularisation	0.46 (0.44-0.48)	< 0.001	0.66 (0.63-0.69)	< 0.001	0.46 (0.45-0.47)	< 0.001	0.57 (0.55-0.58)	< 0.001

Table S5. Unadjusted and adjusted odd ratios with 95% CIs for STEMI and NSTEMI women who received treatment at discharge compared with men

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; reperfusion, fibrinolysis or primary percutaneous coronary intervention [PCI]; revascularisation, PCI or coronary artery bypass graft [CABG] surgery; -, not applicable.